Trials / Unknown
UnknownNCT05029102
TAS-102 and Anlotinib in ≥3 Lines mGC
TAS-102 Combined With Anlotinib in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments (THALIA): a Prospective Single-arm Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of TAS-102 and Anlotinib in patients with metastatic gastric cancer who had been treated with ≥ 2 lines of prior standard chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS 102 | 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle |
| DRUG | Anlotinib | 10mg，per oral，once daily，days 1-14 of each 21-day cycle |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2021-08-31
- Last updated
- 2024-02-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05029102. Inclusion in this directory is not an endorsement.